Clinical Trial Update: A Study of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects With Metastatic Urothelial Cancer and Other Malignant Solid Tumors That Express Nectin-4 [Phase 1]

View source ↗

Summary

Phase 1 dose-escalation study of ASG-22CE as monotherapy in metastatic urothelial cancer and other nectin-4 expressing solid tumors has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urothelial Cancer

Drugs mentioned

• ASG-22CE

Snippet

Sponsor: Astellas Pharma Global Development, Inc. | Conditions: Metastatic Urothelial Cancer and Other Malignant Solid Tumors | Phase 1 | Status: COMPLETED